Dialectica supported a top-50 European private equity investor at the start of a due diligence project in the biotechnology sector. Working on a time-sensitive deadline, they were eager to get answers to their critical questions as fast and efficiently as possible, looking to receive forward-looking insights from the best subject matter experts in the industry.
Our client got the latest commercial insights around the market and regulatory trends. They analyzed the competitive landscape and the key purchasing criteria from senior industry experts that had recently exited the business. Dialectica also offered access to key decision makers from validated customers of the target firm that helped the private equity investor evaluate the medium term viability of the business, and inform their decision to move ahead with the potential acquisition.